Author/Editor		Preložnik-Zupan, Irena
Title		Akutna mieloblastna levkemija: retrospektivna analiza odraslih bolnikov, ki smo jih zdravili po protokolu MRC AML 10
Translated title		Acute myeloid leukemia: a retrospective analysis of MRC AML 10 treated adult patients
Type		članek
Source		Med Razgl
Vol. and No.		Letnik 39, št. Suppl 5
Publication year		2000
Volume		str. 117-22
Language		slo
Abstract		Background. Acute myeloid leukemias (AML) refer to a group of hematopoietic neoplasms involving cells commited to the myeloid line of cellular development. During the past 20 years the outcome of treatment of AML in younger patients has improved substantially. The general evolution in the therapeutic strategy has been a more aggresive treatment early in first complete remission. We report our experiences with MRC AML 10 treated petients. Methods. On the Department of Haematology in Ljubljana, 54 young adults AML patients (27 men, 27 women) were treated with MRC AML 10 protocol, from January 1994 to September 2000. The median age of the patients was 44 years. Results. At the end of the induction therapy 35 (65%) patients achieved complete remission (CR). 13 patients were transplanted (5 autologous, 8 allogeneic). The median of the overall survival was 11 months, the estimated rate of survival at 3 years was 27%. The median relaps-free survival duration was 19 months. Conclusions. The optimum amount of treatment for young adults patients with AML has not yet been defined in the literature. It is clear that autologous and allogeneic bone marrow transplantation (BMT) can further reduce the risk of relapse in all groups of patients. For BMT to achieve its potential, the technique must be made safer.
Summary		Izhodišča. Akutne mieloblastne levkemije (AML) so skupina neoplazem krvotvornega sistema, ki prizadenejo nezrele celice mieloične vrste. Zdravljenje AML pri mlajših odraslih bolnikih se je v zadnjih 20 letih izboljšalo. Glavna novost je bolj intenzivno vzdrževalno zdravljenje v prvi popolni remisiji. V prispevku smo prikazali naše izkušnje pri zdravljenju mlajših odraslih bolnikov z AML po protokolu MRC (Medical Research Council) AML 10. Metode. Od januarja 1994 do septembra 2000 smo na Kliničnem oddelku za hematologijo zdravili 54 mlajših odraslih bolnikov (27 moških in 27 žensk) z AML po protokolu MRC AML 10. Mediana starosti bolnikov ob ugotovitvi bolezni je bila 44 let. Rezultati. Remisijo bolezni smo dosegli pri 35 (65 %) bolnikih po zaključenem indukcijskem zdravljenju. Presaditev krvotvornih matičnih celic (PKMC) smo opravili pri 13 bolnikih (8 alogeničnih in 5 avtolognih). Mediana preživetja vseh bolnikov je bila 11 mesecev, verjetnost 3-letnega preživetja pa 27 %. Mediana trajanja remisije je bila 19 mesecev. Zaključki. V literaturi še ni jasnih zaključkov, katera oblika zdravljenja je optimalna za mlajše odrasle bolnike z AML. Jasno je, da tako alogenična kot avtologna PKMC zmanjšata verjetnost ponovitve bolezni pri vseh skupinah bolnikov. Potrebno pa je doseči večjo varnost PKMC, saj je smrtnost zaradi nje še vedno zelo velika.
Descriptors		LEUKEMIA, MYELOCYTIC, ACUTE ADULT DISEASE-FREE SURVIVAL SURVIVAL ANALYSIS